Allergy Unit, Fundación Valle De Lili, Cali, Colombia.
Allergy Unit, Fundación Valle De Lili, Cali, Colombia,
Int Arch Allergy Immunol. 2021;182(5):433-439. doi: 10.1159/000512072. Epub 2021 Feb 16.
Hypersensitivity reactions to nonsteroidal anti-inflammatory drugs (NSAIDs) are common. These patients require an effective and safe analgesic alternative.
The aim of the study was to demonstrate the safety of meloxicam and etoricoxib administered by open oral challenge in 2 equal steps in patients with NSAID hypersensitivity.
A cross-sectional, descriptive study of patients with a diagnosis of NSAID hypersensitivity who underwent an oral drug provocation test (DPT) with meloxicam or etoricoxib between January 2011 and August 2017 was conducted. The analysis was performed from a database in BD Clinic.
Two hundred and twenty-eight oral provocations were performed with an alternative NSAID (203 with meloxicam and 25 with etoricoxib) in 217 patients with hypersensitivity to NSAIDs. The median age was 38 years. Ninety-eight percent of meloxicam and 100% of etoricoxib DPTs were performed in 2 steps (without previous placebo), and 52% and 64% of meloxicam and etoricoxib DPTs, respectively, were performed with 50% of the therapeutic dose in each step. Tolerance to meloxicam was demonstrated in 192 patients (94.5%) and in 100% of patients receiving etoricoxib.
Open oral provocation with meloxicam and etoricoxib carried out in 2 steps without placebo seems to be safe and implies less costs and less time expenditure. Also, it could be performed with 2 equal doses.
非甾体抗炎药（NSAIDs）过敏反应很常见。这些患者需要一种有效且安全的替代镇痛药物。
本研究旨在证明在 NSAIDs 过敏患者中，以开放口服挑战的方式分 2 步给予美洛昔康和依托考昔的安全性。
这是一项回顾性、描述性研究，纳入了 2011 年 1 月至 2017 年 8 月间接受美洛昔康或依托考昔口服药物激发试验（DPT）的 NSAIDs 过敏患者。分析基于 BD 诊所的数据库进行。
在 217 例对 NSAIDs 过敏的患者中进行了 228 次替代 NSAID 的口服激发（203 次使用美洛昔康，25 次使用依托考昔）。中位年龄为 38 岁。98%的美洛昔康和 100%的依托考昔 DPT 分 2 步进行（无安慰剂），52%和 64%的美洛昔康和依托考昔 DPT 分别以每个步骤中 50%的治疗剂量进行。192 例（94.5%）患者对美洛昔康耐受，100%的患者对依托考昔耐受。
无需安慰剂的分 2 步开放口服激发试验中使用美洛昔康和依托考昔似乎是安全的，这意味着成本更低、时间消耗更少。也可以使用 2 个相等的剂量进行。
